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CTLA-4 Signaling Regulates the Intensity of Hypersensitivity
Responses to Food Antigens, but is Not Decisive in the
Induction of Sensitization
Femke van Wijk,1*‡ Sanne Hoeks,* Stefan Nierkens,* Stef J. Koppelman,§ Peter van Kooten,†
Louis Boon,¶ Le´on M. J. Knippels,‡ and Raymond Pieters*
Although food allergy has emerged as a major health problem, the mechanisms that are decisive in the development of sensiti-
zation to dietary Ag remain largely unknown. CTLA-4 signaling negatively regulates immune activation, and may play a crucial
role in preventing induction and/or progression of sensitization to food Ag. To elucidate the role of CTLA-4 signaling in responses
to food allergens, a murine model of peanut allergy was used. During oral exposure to peanut protein extract (PPE) together with
the mucosal adjuvant cholera toxin (CT), which induces peanut allergy, CTLA-4 ligation was prevented using a CTLA-4 mAb.
Additionally, the effect of inhibition of the CTLA-4 pathway on oral exposure to PPE in the absence of CT, which leads to
unresponsiveness to peanut Ag, was explored. During sensitization, anti-CTLA-4 treatment considerably enhanced IgE responses
to PPE and the peanut allergens, Ara h 1, Ara h 3, and Ara h 6, resulting in elevated mast cell degranulation upon an oral challenge.
Remarkably, antagonizing CTLA-4 during exposure to PPE in the absence of CT resulted in significant induction of Th2 cytokines
and an elevation in total serum IgE levels, but failed to induce allergen-specific IgE responses and mast cell degranulation upon
a PPE challenge. These results indicate that CTLA-4 signaling is not the crucial factor in preventing sensitization to food allergens,
but plays a pivotal role in regulating the intensity of a food allergic sensitization response. Furthermore, these data indicate that
a profoundly Th2-biased cytokine environment is insufficient to induce allergic responses against dietary Ag. The Journal of
Immunology, 2005, 174: 174–179.
F ood allergy, which results from adverse immune responsesto dietary Ag, affects 2% of the American population(1). Peanut allergy is responsible for the majority of fatal
food-induced allergic reactions (2), and the prevalence of peanut
allergy seems to be increasing. Recently, progress has been made
in the treatment of clinical symptoms in peanut allergic patients
(3), but mechanisms responsible for the induction of sensitization
to food allergens remain largely unknown.
Mucosal immune responses to orally ingested food Ag are gen-
erally based on Ag exclusion and suppressive immunity leading to
“oral tolerance” (reviewed in Ref. 4). In the case of allergic hy-
persensitivity to food Ag, oral tolerance is abrogated. Because co-
stimulation is required for effective immunity, signals delivered by
different costimulatory pathways—stimulatory or suppressive—
may play a critical role in the balance between oral sensitization
and tolerance induction.
The interaction between CD28 on T cells, and its two ligands
B7-1 (CD80) and B7-2 (CD86) on APC is considered to be the
master costimulatory pathway for optimal T cell responses (5). In
contrast to the stimulatory signals provided by CD28, interaction
of CD80/CD86 with the CD28 homologue CTLA-4 provides sig-
nals that down-modulate T cell activation. Antagonizing CTLA-4
signaling enhances T cell proliferation (6), whereas cross-linking
of CTLA-4 in vitro inhibits anti-CD3-induced T cell proliferation
(7). Furthermore, CTLA-4-deficient mice develop a fatal lympho-
proliferative disease (8), showing a role for CTLA-4 in the estab-
lishment of peripheral self tolerance, as well as regulation of active
immunity.
Although very little is known about the role of the CD28-
CTLA-4/B7 pathway in food allergy, anti-CTLA-4 treatment has
been shown to abrogate systemic hyporesponsiveness to orally ad-
ministered OVA in oral tolerance models (9, 10). This suggests
that CTLA-4 signaling might be decisive in oral tolerance devel-
opment. In addition, recent studies in murine models of allergic
asthma (a comparable Th2-induced mucosal hypersensitivity re-
sponse) suggest an indispensable role for the CTLA-4 signaling
pathway in controlling the production of Th2 cytokines, and in the
development of airway hyperresponsiveness. As such, inhibition
of CD28-B7 interaction ameliorated (11), and even reversed asth-
matic manifestations (12), whereas the blockade of CTLA-4 en-
hanced allergic sensitization (13). In line with these observations,
we hypothesized that CTLA-4 is involved in suppressing the in-
duction and progression of sensitization to food proteins.
To test this hypothesis, an established oral peanut sensitization
model (with minor modifications) was used. In this model, expo-
sure to peanut extract (PPE)2 in the presence of the mucosal ad-
juvant cholera toxin (CT) induces sensitization to peanut, charac-
terized by PPE- and peanut allergen (Ara h)-specific IgE serum Ab
and cytokine production, and subsequent clinical reactions (14). In
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the present study, mice were treated with the mAb 4F-10 to inhibit
the CTLA-4 signaling pathway, and the effects on parameters in an
early and later phase of sensitization were explored. In agreement
with our hypothesis, anti-CTLA-4 treatment resulted in enhanced
sensitization to PPE and the purified peanut allergens Ara h 1, Ara
h 3, and Ara h 6, characterized by a profound elevation of specific-
IgE production, and increased clinical reaction upon an oral
challenge.
Additionally, the effect of anti-CTLA-4 treatment on oral expo-
sure to PPE without adjuvant, which results in unresponsiveness to
peanut Ag (no PPE- or allergen-specific IgE), was investigated.
Despite the induction of Th2 cytokines, activation of APC, and an
elevation in total serum IgE levels, anti-CTLA-4 treatment failed
to induce PPE-specific or Ara h-specific IgE Abs or mast cell
degranulation.
These results suggest that CTLA-4 signaling plays an important
role in regulation of the intensity of hypersensitivity responses to
food proteins, but is not decisive in preventing the induction of
sensitization to dietary Ag. Moreover, current data challenge the




Female, specific, pathogen-free C3H/HeOuJ Ico mice, 4 wks of age, were
purchased from Charles River Laboratories and were maintained under
barrier conditions in filter-topped macrolon cages with wood chip bedding,
at mean temperature of 23  2°C, 50–55% relative humidity, and a 12-h
light/dark cycle. Drinking water and standard laboratory food pellets were
provided ad libitum. The experiments were approved by the Animal Ex-
periments Committee of the Faculty of Veterinary Medicine, Utrecht Uni-
versity.
Chemicals and reagents and mAbs
Chemicals were obtained from Sigma-Aldrich unless stated otherwise.
Cells producing anti-CTLA-4 (4F-10) were obtained from American Type
Culture Collection and Abs were purified using thiophilic agarose
(SeaKem). Purified hamster IgG (Rockland Immunochemicals) was used
as an isotype control. For cytokine measurements, IL-4, IL-5, and IFN-
capture and detecting Abs, and IL-10 ELISA kit were obtained from BD
Pharmingen and streptavidin-HRP from Sanquin. BD Pharmingen was the
supplier of rat anti-mouse IgE and the digoxigenin (DIG)-coupling kit was
obtained from Boehringer Mannheim and anti-DIG-peroxidase Fab from
Roche Diagnostics. Alkaline phosphatase (AP)-conjugated goat anti-
mouse, human adsorbed IgG1, IgG2a, and AP-conjugated rat anti-mouse
IgE were purchased from Southern Biotechnology Associates. Campina
Melkuni was the supplier of milk powder used in blocking buffer. Mouse
Ig reference serum with 2 g/ml monoclonal DNP-specific IgE was ob-
tained from Valeant. Medium that was used for the in vitro restimulation
was complete RPMI 1640 with Glutamax-I (Invitrogen Life Technologies)
supplemented with 10% FCS (Valeant) and 2% penicillin-streptomycin.
Preparation of PPE and purification of allergens
Peanuts from the Runner cultivar (Cargill) were kindly provided by Imko
Nut Products. The PPE was prepared as described by Koppelman et al.
(15). Briefly, peanuts were ground and the protein was extracted by mixing
25 g of ground peanut with 20 ml of 20 mM Tris buffer (pH 7.2). After 2 h
stirring at room temperature, the aqueous fraction was collected by cen-
trifugation (3000 g for 30 min) and subsequently centrifuged at 10000
g for 30 min to remove residual traces of fat and insoluble particles. The
extract contained 30 mg/ml protein as determined by Bradford analysis
with BSA as a standard. SDS-PAGE analysis confirmed the presence of
proteins migrating at the same molecular weights as the purified allergens
Ara h 1, Ara h 3, and Ara h 6 (data not shown). The allergens, Ara h 1 and
Ara h 3, were purified as described by Koppelman et al. (15), and Ara h 6
was purified from a side fraction.
Treatment protocol
Mice (n  6) were orally exposed to PPE plus CT, PPE alone, or were left
untreated. Oral exposure to PPE was performed by intragastric dosing of 6
mg of roasted PPE on 3 consecutive days, followed by weekly dosing of 6
mg of PPE (4 wks). CT (10 g) was coadministered on days 1, 2, 3, 8, 15,
and 21. Equivalent groups (n  6) were additionally injected i.p. with 100
g of anti-CTLA-4 mAb on days 1, 3, 7, 14, and 20 during the oral-dosing
regime. PPE-exposed mice were also treated with an appropriate isotype
control, which had no effect on any of the measured (data not shown). At
day 30, mice received an oral challenge with 12 mg of PPE. Mice were
killed by cervical dislocation on day 7 or 31 days after the onset of
exposure.
Measurement of serum IgG1, IgG2a, and IgE Abs
Blood was collected at weekly intervals and levels of PPE and Ara h-
specific Abs were measured by ELISA (IgG1 and IgG2a) or sandwich
ELISA (IgE). Plates (highbond 3590; Costar) were coated overnight with
20 g/ml PPE or Ara h (for IgG1 and IgG2a detection) or with 1.5 g/ml
purified rat anti-mouse IgE (for Ag-specific and total serum IgE detection)
in carbonate buffer (pH 9.6), followed by 1-h blocking (37°C) with PBS-
Tween/3% milk powder. Each test serum was titrated starting at 1/8 or 1/16
dilution and incubated for 1 h (37°C). A presera pool was used as reference
value (dilution 1/4) for Ag-specific Ab levels, and a standard curve of a
reference serum (2 g/ml IgE) was used to determine total serum IgE
levels. For detection of IgG1 and IgG2a and total serum IgE Abs, AP-
conjugated Abs were added (1 h at 37°C). Subsequently, 1 mg/ml p-nitro-
phenylphosphate in diethanolamine buffer was used for the color reaction,
which was stopped with a 10% EDTA solution, and absorbance was mea-
sured at 405 nm using an ELISA reader ELX800 (BIOTEK Instruments).
To measure Ag-specific IgE Abs, serum was incubated for 2 h and subse-
quently a PPE- or Ara h-DIG conjugate solution was added (1 h at 37°C).
The coupling of DIG to PPE or the Ara h’s was performed according to the
manufacturer’s instructions. Briefly, the coupled proteins were separated
on a sephadex G-25 column and labeling efficiency was determined spec-
trophotometrically at 280 nm. After incubation (1 h at 37°C) with perox-
idase-conjugated anti-DIG fragments, a tetramethylbenzidine substrate (0.1
mg/ml) solution was used and the color reaction was stopped with 2 M
H2SO4. Absorbance was measured at 450 nm. The reciprocal of the furthest
test serum dilution resulting in an extinction higher than the reference value
was read as a titer.
Cell culture and cytokine measurement
Spleen and mesenteric lymph node (MLN) single-cell suspensions (150 l
of 2.5  106 cells/ml in complete RPMI 1640) were incubated in the
presence or absence of PPE (200 g/ml) in 96-well plates for 96 h at 37°C,
5% CO2. After centrifugation for 10 min at 150  g, supernatant was
collected and stored at 20°C until analysis.
In the culture supernatants, IFN-, IL-4, IL-5, and IL-10 were deter-
mined by sandwich ELISA. Plates (highbond 3590; Costar) were coated
overnight with 1.5 g/ml rat anti-mouse IL-4, IL-5, or IFN-, and the
following day, plates were blocked with PBS-Tween/3% milk powder for
4 h at room temperature. Samples and cytokine standards were added in
several dilutions and incubated overnight at 4°C. Plates were incubated
with 0.25 g/ml rat-anti-mouse IL-4, IL-5, or IFN- conjugate for 1 h at
room temperature, followed by streptavidin-HRP incubation for 45 min.
Finally, tetramethylbenzidine substrate (0.1 mg/ml) was added and the
color reaction was stopped with 2 M H2SO4. Absorbance was measured at
450 nm. The IL-10 ELISA was performed in accordance with the manu-
facturer’s instructions.
Measurement of serum mouse mast cell protease-1 (mmcp-1)
Blood was collected before, and 1 h after, an oral challenge with PPE at
day 30, and serum levels of mmcp-1 were determined with an ELISA kit
(Moredun). The ELISA was performed according to the manufacturer’s
instructions.
Statistical analysis
Data were analyzed using SigmaStat statistical software package (SPSS,
Chicago, IL). For serum Ab levels, cytokine levels, and mmcp-1 serum
levels, the differences between group means (log-transformed data) were
determined by using one-way ANOVA with Bonferroni as post hoc test.
Values of p  0.05 were considered statistically significant.
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Results
Different effects of antagonizing CTLA-4 on PPE-specific Ab
levels in the absence or presence of an adjuvant
Mice were orally exposed to PPE in the presence or absence of the
mucosal adjuvant CT. Additionally, both PPE- and PPE plus CT-
exposed mice were treated with anti-CTLA-4 mAb or did not re-
ceive mAb treatment.
The group receiving 4 wks of oral treatment with PPE plus CT
showed PPE-specific serum IgG1, IgG2a, and IgE (Fig. 1). Block-
ade of CTLA-4 during the oral sensitization protocol increased
( p  0.01) both Th2-related (IgG1 and IgE) and Th1-related
(IgG2a) PPE-specific Ab levels compared with PPE plus CT treat-
ment group.
The group that was exposed to PPE without CT produced low
levels of PPE-specific IgG1 and IgG2a and no IgE. In the similarly
exposed group, blockade of CTLA-4 had no effect on Ab levels,
demonstrating that hyporesponsiveness to peanut upon oral PPE
exposure without adjuvant is not abrogated by anti-CTLA-4
treatment.
Anti-CTLA-4 treatment increases total serum IgE levels
In contrast to PPE-specific IgE levels, anti-CTLA-4 treatment
clearly augmented total IgE production in both PPE-exposed
groups (irrespective of the presence of CT, see Fig. 2). Mice
treated with anti-CTLA-4 without oral dosing of PPE showed a
similar significant elevation of total IgE serum levels compared
with control mice that received no treatment at all. These data
demonstrate a prominent role for T cells expressing CTLA-4 in
regulating total circulating IgE levels.
Anti-CTLA-4 treatment increases Ara h-specific IgE serum levels
in sensitized mice
The remarkable differences between PPE-specific IgE and total
IgE levels following CTLA-4 blockade warranted further evalua-
tion of Ag-specific IgE responses.
PPE consists of different peanut proteins, and we have earlier
demonstrated that it is possible to determine specific serum IgE
Abs against individual proteins from the extract (16). Several pea-
nut proteins are recognized by serum IgE of peanut allergic pa-
tients and these allergens are referred to as Ara h 1-7 (17). In the
current study, we used the purified allergens Ara h 1, Ara h 3, and
the minor allergen Ara h 6 to measure allergen-specific serum IgE
FIGURE 1. Effect of anti-CTLA-4 treatment on PPE-specific Ab pro-
duction. PPE-specific Th1-associated (IgG2a) and Th2-associated (IgG1
and IgE) serum Ab levels were determined after 4 wks of oral PPE expo-
sure in the presence or absence of CT and with or without anti-CTLA-4
mAb (aCTLA-4) treatment. The data are presented as the mean 2log Ab
titer  SEM of six mice per group. , Significantly different (p  0.01)
from the corresponding non-CTLA-4-treated group. #, Significantly differ-
ent (p  0.01) from the corresponding non-CT-exposed group.
FIGURE 2. Effect of anti-CTLA-4 treatment on total serum IgE levels.
Mice were orally exposed to PPE with or without CT or were left untreated
(control). Indicated groups received blocking anti-CTLA-4 mAb
(aCTLA-4) during the oral exposure protocol. Total serum IgE levels were
measured by ELISA after 4 wks of dosing. The data are presented on a log
scale as the group mean  SD of six mice per group. , Significantly
different (p  0.01) from corresponding non-anti-CTLA-4-treated group.
FIGURE 3. Effect of CTLA-4 blockade on allergen-specific IgE Ab re-
sponses. Serum IgE Ab levels against the purified peanut allergens Ara h
1, Ara h 3, and Ara h 6 were determined after 4 wks of oral PPE exposure
in the presence or absence of CT. Indicated groups received blocking anti-
CTLA-4 mAb (aCTLA-4) during the oral exposure protocol. Ara h-specific
IgE Ab levels were measured in pooled sera (six mice per group) using a
sandwich ELISA.
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responses upon oral PPE exposure. Treatment with PPE plus CT
for 4 wks induced low levels of allergen-specific IgE (Fig. 3).
Blockade of CTLA-4 in this group resulted in a profound increase
of allergen-specific IgE levels with the highest responses against
Ara h 1, followed by Ara h 3 and Ara h 6.
No allergen-specific IgE was found after oral exposure to PPE
alone. Treatment with anti-CTLA-4 mAb during PPE exposure in
the absence of adjuvant did not provoke IgE responses against Ara
h 1, Ara h 3, or Ara h 6, confirming that CTLA-4 blockade does
not overcome the IgE unresponsiveness to peanut allergens in mice
that are orally exposed to PPE without an adjuvant.
Anti-CTLA-4 treatment enhances mast cell degranulation upon
oral challenge with PPE
Clinical symptoms in peanut allergic patients are caused by mast
cell mediators that are released upon ingestion of peanut. In the
current murine model, mast cell degranulation upon an oral chal-
lenge with PPE was determined by measuring serum levels of the
mast cell mediator mmcp-1 before and after challenge. Treatment
with PPE plus CT induced a significant elevation of mmcp-1 se-
rum levels after challenge compared with control and PPE-treated
mice (Fig. 4).
Anti-CTLA-4 treatment induced higher base levels of serum
mmcp-1 before oral challenge compared with levels in non-anti-
CTLA-4-exposed animals. Blockade of CTLA-4 only induced an
increase in mmcp-1 serum concentration after oral challenge in the
PPE plus CT treatment group, with mmcp-1 levels being four
times higher than in the PPE plus CT treatment group. These re-
sults demonstrate that the challenge response to PPE is exacer-
bated by anti-CTLA-4 treatment.
Enhancement of Th2-related cytokine production upon
anti-CTLA-4 treatment
The cytokine environment plays an important role in the develop-
ment of sensitization to food proteins, including the production of
FIGURE 4. Effect of anti-CTLA-4 treatment on mmcp-1 serum levels
upon an oral challenge with PPE. Mice were orally exposed to PPE with or
without CT or were left untreated (control). Indicated groups received
blocking anti-CTLA-4 mAb (aCTLA-4) during the oral exposure protocol.
Four weeks after the initial exposure all groups received an oral challenge
with 12 mg of PPE. Levels of mmcp-1 were determined by ELISA in blood
samples collected before and 1 h after the oral challenge. Levels are ex-
pressed as the group mean  SD of six mice per group. , Significantly
different (p  0.05) from corresponding non-anti-CTLA-4-treated group.
#, Significant difference (p 0.05) between levels before and 1 h after oral
challenge.
FIGURE 5. Effect of CTLA-4 blockade on cytokine levels in splenocyte
and MLN cell culture supernatants. Mice were orally exposed to PPE with
or without CT or were left untreated (control). Indicated groups received
blocking anti-CTLA-4 mAb (aCTLA-4) during the oral exposure protocol.
Spleen and MLN cells were removed 4 wks after the initial oral exposure
and were cultured (2.5  106 cells/ml) for 96 h in the presence or absence
of PPE (200 g/ml). Culture supernatants were collected and cytokine
levels of IL-4, IL-5, IL-10, and IFN- were determined by ELISA. Levels
of cytokines induced by restimulation with an irrelevant protein BSA were
similar to levels induced in cultures with medium alone (data not shown).
Data are presented on a log scale as the group mean  SEM of 6 mice per
group. , Significantly different (, p  0.05, , p  0.01) from the
corresponding non-anti-CTLA-4-treated group. #, Significantly different
(p  0.05) from the corresponding non-CT-treated group.
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Ag-specific Abs. Therefore, the effect of CTLA-4 blockade on the
production of IL-4, IL-5, IL-10, and IFN- was investigated, 4 wks
after the onset of exposure to PPE, by culturing single-cell sus-
pensions in the presence or absence of PPE. Treatment with anti-
CTLA-4 significantly enhanced Th2-associated (IL-4 and IL-5)
and T regulatory (Tr)-related (IL-10) cytokine production in both
MLN and spleen independent of PPE or CT administration (Fig.
5). Cells cultured in the presence or absence of PPE produced
comparable amounts of IL-4, IL-5, and IL-10, indicating that the
stimulation of cytokine production was polyclonal. This implies
that a Th2 cytokine environment is not the key factor in sensiti-
zation to PPE.
Levels of the Th1-associated cytokine IFN- were also elevated
in the anti-CTLA-4-treated groups (Fig. 5). However, coadminis-
tration of the adjuvant CT significantly elevated IFN- levels com-
pared with levels in the non-CT-exposed groups. Furthermore,
dosing with PPE plus CT induced Ag-specific IFN-, illustrated by
significantly higher levels in cultures restimulated with PPE.
Because development of sensitization to food proteins occurs
already in an early phase of exposure, we additionally examined
the effect of CTLA-4 blockade early (7 days after the primary
exposure to PPE) in the response. Also in an early stage, anti-
CTLA-4 treatment strongly induced IL-5, IL-10, and IFN- cyto-
kine production in cultures of both spleen and MLN compared
with non-mAb-injected groups (data not shown).
Conclusively, CTLA-4 blockade induces non-PPE-specific
IL-4, IL-5, and IL-10 production in both spleen and MLN, whereas
the adjuvant CT seems to be the most important factor for the
induction of IFN- production.
Discussion
In the current study, the involvement of CTLA-4 signaling in im-
mune responses to oral food allergens was investigated and it was
demonstrated that CTLA-4 regulates the intensity of a food aller-
gic response but is not decisive in the induction of sensitization.
Blockade of functional CTLA-4 signaling during oral sensitiza-
tion to PPE plus CT resulted in enhanced IgE responses against
PPE and the peanut allergens, Ara h 1, Ara h 3, and Ara h 6,
leading to a more pronounced mast cell degranulation response
upon oral challenge with PPE. Disease exacerbation was accom-
panied by an increased production of Th2-associated cytokines
(IL-4, IL-5, and IL-10) and the Th1-associated cytokine IFN- in
both spleen and MLN.
CTLA-4 signaling thus seems to play a pivotal role in regulating
the intensity of food allergic responses. Similarly, Hellings and
colleagues (13) demonstrated an aggravation of Th2-mediated al-
lergic airway disease during anti-CTLA-4 treatment. Furthermore,
in humans, CTLA-4 promoter polymorphism has been linked to
total serum IgE levels (18) and bronchial hyperresponsivity (19) in
asthmatic patients, meaning CTLA-4 is implicated in regulating
the intensity of allergic disease. Several nonmutually exclusive
mechanisms can be proposed that may underlie regulation of an
allergic response by CTLA-4 signaling. CTLA-4 engagement may
have a direct suppressive effect on Th2 cells as shown by Ooster-
wegel and colleagues (20). Furthermore, CTLA-4 is also expressed
on B cells, and CTLA-4 signaling on these cells has been shown
to inhibit IL-4-driven isotype switching, thereby possibly prevent-
ing allergen-specific IgG1 and IgE production (21). Thus, in the
present study, anti-CTLA-4 treatment may have directly affected T
and B cell responses, resulting in increased Th2-associated re-
sponses against PPE allergens and concomitant aggravated food
allergic disease. CTLA-4 inhibition may additionally have an in-
direct effect via CD4CD25 Tr cells that down-regulate immune
responses in a polyclonal fashion. In the mouse intestine, this pop-
ulation of Tr cells has been shown to constitutively express
CTLA-4 and is able to control intestinal inflammation (22). Cross-
linking of CTLA-4 (resulting in CTLA-4 signaling) can induce
TGF- production by murine CD4 T cells (23) and the suppres-
sive effect of these Tr cells has been demonstrated to be TGF-
dependent (22). The disruption of Tr cell function by anti-CTLA-4
treatment may have played an important role in the increased im-
mune responses against peanut allergens that were observed in the
present study.
Besides the role of CTLA-4 in regulating the intensity of an
allergic response, it was investigated whether abrogation of
CTLA-4 signaling also resulted in the induction of active immu-
nity against oral Ag. It has been suggested that CTLA-4 is required
for oral tolerance induction. However, this remains controversial
because it has been reported that CTLA-4 blockade can abolish
oral tolerance induced by oral exposure to OVA (9, 10, 24), while
others have reported that CTLA-4 blockade failed to overcome
development of oral tolerance to OVA in a similar model (25). In
the present model, mice orally exposed to peanut without adjuvant
do not develop PPE-specific IgE and only very low IgG responses.
We hypothesized that inhibition of CTLA-4 would abrogate this
“unresponsiveness” to peanut proteins and would induce a produc-
tive PPE-specific humoral response. However, anti-CTLA-4 treat-
ment failed to induce PPE- or Ara h-specific IgE Ab responses
following PPE exposure, suggesting that CTLA-4 signaling is not
decisive for the induction of sensitization to food proteins. Ac-
cordingly, in contrast to the severity of asthma, no significant as-
sociation between incidence of asthma or atopy and the CTLA-4
polymorphic loci has been found in humans (18).
Because we demonstrated that an allergic response to food
Ag is not initiated by CTLA-4 blockade, the question remains
which factors are responsible for the development of sensitiza-
tion to food proteins. In the present model, coadministration of
the mucosal adjuvant CT turned out to be crucial for the induc-
tion of sensitization to PPE. CT is thought to stimulate Th2-
dependent immune responses to a bystander Ag by provoking
Th2 cytokine production (26). This phenomenon was also ob-
served—-to a much larger extent— upon anti-CTLA-4 treat-
ment. Thus, our results suggest that excessive Th2 cytokine
production per se is insufficient for the development of active
immunity against food proteins and challenge the concept of
Th2-bias as the key factor for food allergy (27).
For the induction of sensitization, a significant proportion of the
intact protein has to be absorbed by the intestine and in food-
allergic patients increased protein absorption has been reported.
Thus, an alternative explanation for the impact of CT may be the
influence on (systemic) availability of bystander Ag for the im-
mune system. The most prominent effect of CT in the present
experiments was PPE-induced IFN- production. One of the ef-
fects attributed to IFN- is the induction of changes in epithelial
permeability and intestinal integrity (28). Additionally, CT itself
promotes dendritic cell activation (29, 30) and migration (31),
which facilitates Ag presentation to the immune system.
Anti-CTLA-4 treatment (with or without PPE) induced a pro-
found increase in total serum IgE levels and polyclonal Th2 cyto-
kine production. Blocking CTLA-4/B7 interaction promotes Th2
differentiation (20), which may explain the observed excessive
Th2 cytokine production and IgE levels. It has also been shown
that CTLA-4 plays a major role in down-regulating autoaggressive
T cells (32, 33) and that CTLA-4-deficient mice develop a fatal
lymphoproliferative autoimmune disorder (8). Concurring, in the
present study, higher levels of IgG Abs against ssDNA-specific
were found in the serum of anti-CTLA-4-treated mice compared
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with control mice (data not shown), suggesting autoantibody for-
mation upon anti-CTLA-4 exposure.
The elevated levels of the mast cell mediator mmcp-1 that were
observed upon anti-CTLA-4 treatment (in the absence of oral Ag)
demonstrate that mast cells are also affected by anti-CTLA-4 treat-
ment. The high production of IL-4 and IL-10 cytokines and serum
IgE Abs in anti-CTLA-4-treated mice may have enhanced mast
cell proliferation and differentiation as described by Lukacs and
colleagues (34). In addition, the CTLA-4 ligands CD80 and CD86
are expressed on mast cells (35). It is unknown whether ligation of
CTLA-4 with these molecules may have a direct suppressive effect
on mast cells, but it might be another explanation for the observed
mast cell degranulation upon anti-CTLA-4 treatment.
Taken together, these results suggest that in food allergy
CTLA-4 signaling is involved in regulating the intensity of the
hypersensitivity responses, but is not decisive for induction of sen-
sitization to orally ingested Ag. Accordingly, CTLA-4 may repre-
sent a potential target for treatment of food allergic disorders. Fur-
thermore, these findings imply that the initiation of food allergy
requires another crucial factor in addition to a Th2 cytokine
environment.
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